Medical Technology

@xconomy.com 3 years ago

Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally

@xconomy.com 3 years ago

Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases

@xconomy.com 4 years ago

Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy

@xconomy.com 4 years ago

Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More

@xconomy.com 4 years ago

Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic

@xconomy.com 4 years ago

Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further

@xconomy.com 4 years ago

Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds

@xconomy.com 5 years ago

In Landmark Gene-Editing Study, Sangamo Reports Little Benefit

@xconomy.com 5 years ago

To Boost Cancer Pipeline, Gilead Bets at Least $50M on Startup Tango

@xconomy.com 5 years ago

TP Therapeutics Names New CEO, Gets $80M More For Cancer Drug Push

@xconomy.com 5 years ago

Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More

@xconomy.com 5 years ago

IPO Wave Rolls On as Five Life Science Firms Haul in $651M

@xconomy.com 5 years ago

Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M

@xconomy.com 6 years ago

United Therapeutics Reaches $141M Deal for PAH Drug Firm SteadyMed